Portfolio Sync Solutions
Streamline your investment strategy with our portfolio synchronization tools. Seamlessly manage and track your holdings across platforms for enhanced
GET STARTEDQuarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
---|---|---|---|---|
Q1 2024 | 1 | $0.60 | $0.60 | $0.60 |
Q2 2024 | 1 | -$0.00 | -$0.00 | -$0.00 |
Q3 2024 | 1 | $0.66 | $0.67 | $0.66 |
Q4 2024 | 3 | $0.43 | $0.92 | $0.68 |
Q1 2025 | 2 | $0.39 | $0.81 | $0.64 |
Q2 2025 | 1 | $0.73 | $0.80 | $0.76 |
Q3 2025 | 1 | $0.79 | $0.88 | $0.83 |
Q4 2025 | 1 | $0.84 | $0.93 | $0.88 |
Q1 2026 | 1 | $0.85 | $0.94 | $0.89 |
Q2 2026 | 1 | $1.00 | $1.10 | $1.04 |
Q3 2026 | 1 | $1.09 | $1.20 | $1.14 |
Q4 2026 | 1 | $1.15 | $1.27 | $1.20 |
Harmony Biosciences Holdings, Inc. last posted its earnings results on Tuesday, October 29th, 2024. The company reported $0.79 earnings per share for the quarter, topping analysts' consensus estimates of $0.67 by $0.12. The company had revenue of 186.04 M for the quarter and had revenue of 582.02 M for the year. Harmony Biosciences Holdings, Inc. has generated $2 earnings per share over the last year ($2.13 diluted earnings per share) and currently has a price-to-earnings ratio of 16.21. Harmony Biosciences Holdings, Inc. has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Thursday, February 20th, 2025 based on prior year's report dates.
Date | Quarter | Consensus Estimate | Reported EPS | Beat/Miss | Revenue Estimate | Actual Revenue |
---|---|---|---|---|---|---|
10/29/2024 | Q3 2024 | $0.67 | $0.81 | 0.14 | $184.07 M | $186.04 M |
08/06/2024 | Q2 2024 | -$0.06 | $0.20 | 0.26 | $172.53 M | $172.81 M |
04/30/2024 | Q1 2024 | $0.60 | $0.68 | 0.08 | $154.62 M | |
02/28/2024 | Q4 2023 | $0.46 | $168.41 M | |||
10/31/2023 | Q3 2023 | $0.65 | $0.64 | -0.01 | $147.83 M | $160.27 M |
08/01/2023 | Q2 2023 | $0.63 | $0.57 | -0.06 | $142.01 M | $134.22 M |
05/02/2023 | Q1 2023 | $0.44 | $0.49 | 0.05 | $119.13 M | |
02/21/2023 | Q4 2022 | $0.58 | $0.82 | 0.24 | $128.31 M | |
11/01/2022 | Q3 2022 | $0.10 | $1.48 | 1.38 | $113.59 M | $117.21 M |
08/02/2022 | Q2 2022 | $0.40 | $0.40 | 0 | $100.73 M | $107.03 M |
05/03/2022 | Q1 2022 | $0.25 | $0.36 | 0.11 | $85.31 M | |
02/28/2022 | Q4 2021 | $0.32 | $0.39 | 0.07 | $91.21 M | |
11/09/2021 | Q3 2021 | $0.27 | -$0.17 | -0.44 | $79.90 M | $80.73 M |
08/10/2021 | Q2 2021 | $0.19 | $0.25 | 0.06 | $68.83 M | $73.82 M |
05/11/2021 | Q1 2021 | $0.02 | $0.13 | 0.11 | $59.67 M | |
03/25/2021 | Q4 2020 | -$0.00 | $56.29 M | |||
11/12/2020 | Q3 2020 | -$0.05 | -$0.14 | -0.09 | $40.00 M | $45.61 M |
06/29/2020 | Q2 2020 | -$0.00 | $38.01 M | |||
03/30/2020 | Q1 2020 | -$0.70 | $19.84 M | |||
12/30/2019 | Q4 2019 | -$0.66 | $6.00 M |
Harmony Biosciences Holdings, Inc. has not confirmed its next earnings publication date, but the company's estimated earnings date is Thursday, February 20th, 2025 based off last year's report dates.
In the previous quarter, Harmony Biosciences Holdings, Inc. (:HRMY) reported $0.79 earnings per share (EPS) to beat the analysts' consensus estimate of $0.67 by $0.12.
The conference call for Harmony Biosciences Holdings, Inc.'s latest earnings report can be listened to online.
The conference call transcript for Harmony Biosciences Holdings, Inc.'s latest earnings report can be read online.
Harmony Biosciences Holdings, Inc. (:HRMY) has a recorded annual revenue of $582.02 M.
Harmony Biosciences Holdings, Inc. (:HRMY) has a recorded net income of $582.02 M. Harmony Biosciences Holdings, Inc. has generated $2.17 earnings per share over the last four quarters.
Harmony Biosciences Holdings, Inc. (:HRMY) has a price-to-earnings ratio of 16.21 and price/earnings-to-growth ratio is 1.89.
Streamline your investment strategy with our portfolio synchronization tools. Seamlessly manage and track your holdings across platforms for enhanced
GET STARTED